

EXINI HAD STRONG PRESENCE AT THE CONGRESSES IN AMSTERDAM AND LUND THIS SPRING

In May the congress ICNC 10 (International Congress in Nuclear Cardiology) in Amsterdam took place as well as the spring meeting for SFNM in Lund. On both occasions EXINI Diagnostics AB was represented by international lecturers who presented their studies on nuclear medicine. Great interests were reflected by the many visits and discussions in the company's booth.

During this spring's large European congress, ICNC 10, in Amsterdam, EXINI were present as exhibitors. Mainly focused to present the new version of the EXINI heart™, but also to discuss the early achievements of the installations in Japan, carried out through agreement with FUJIFILM Pharma co. Ltd. EXINI was also present at the spring meeting of SFNM in Lund, which took place May 18-20.

The response and interest around EXINI and the products are very high for the moment. This is showed not at least in the scientific program in conjunction with congresses. This indicates that EXINI has a good reputation and that the products are considered to have great value to both clinics and patients says Magnus Aurell, CEO, EXINI Diagnostics AB.

ICNC 10 - Nuclear Cardiology and Cardiac CT, 15 - 18 May, 2011 i Amsterdam.

Two clinical studies of EXINI heart were presented as posters during the congress.

- *Comparison of four software packages for quantitative myocardial function., M Lomsky et al*
A large study including 1 052 patients. The result showed that EXINI heart had the best performance of the compared products both in classification normal or abnormal and in the classification of ischemia or no ischemia.
- *Computer assisted diagnosis (CAD) of myocardial perfusion scintigraphy in reference to coronary angiography., P.Dolliner et al*
The conclusion of the study was: "CAD of myocardial perfusions scintigraphy showed a high PPV and NPV in reference to coronary angiography"

Spring meeting of the Swedish Society of Nuclear Medicine, May 18-20 2011 in Lund, Sweden.

Of the 11 presentations and posters in total presented at the spring congress in Lund. Six were linked to EXINI products.

- *"Progression of Disease in Bone in Patients with Prostate Cancer-an Automated Serial Analysis of Whole Body Bone Scans" Reza Kabote et al.*
Conclusion: "A completely automated method for detection of new lesions in serial bone scans can be used for analysis of progression in serial bone scans from prostate cancer patients. Application of the method as a clinical decision support tool or in clinical trials appears to have significant potential."
- *"Bone Scan Index validation using 18F-PET/CT I Prostate Cancer", John Ly et al*
Conclusion: "The authors concluded – The two dimensional BSI method based on whole-body bone scans correlate relative well with the three dimensional PET/CT-BSI on a patient level."

For more information, please contact:

Magnus Aurell, CEO, Phone: 046-286 54 25, E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Brandt and Eden currently has 12 employees. EXINI is listed on the stock market square and has about 250 shareholders. Principal owner, Bo Håkansson.